BridgeBio Pharma Inc (NAS:BBIO)
$ 28.13 -1.14 (-3.89%) Market Cap: 5.27 Bil Enterprise Value: 6.69 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 52/100

BridgeBio Pharma Inc R&D Day Transcript

Sep 29, 2020 / 12:30PM GMT
Release Date Price: $37.1 (+0.71%)
Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, CEO & Director

(presentation)

Thank you all for taking the time to join us today. For those of you that saw that video, there are several important pieces of context in there. We're going to be talking about the R&D that animates us here at BridgeBio. But it's really only important inasmuch as it helps us to serve patients with genetic disease. Elliott, who we've spoken about before, suffers from MOCD Type A. And I'm grateful to say that we have filed and had accepted for priority review by the FDA, or NDA, for that disease. And my hope is, with your support and through repeated application of our R&D engine over the course of the coming years, that Elliott is the first of hundreds of thousands of potentially millions of patients that we can help together.

The second piece of context actually relates to that number, hundreds of thousands or millions. From the get-go of BridgeBio, our ambition has been one of scale and growth. It is not to say that we just want to progress the last couple of products in our pipeline to the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot